Fulgent Genetics/FLGT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Fulgent Genetics

Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.

Ticker

FLGT

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

Headquarters

El monte, United States

Employees

1,184

Fulgent Genetics Metrics

BasicAdvanced
$618M
Market cap
-
P/E ratio
-$5.57
EPS
1.40
Beta
-
Dividend rate
$618M
1.4
$44.09
$19.88
3.7
5.089
0.055
0.14
-13.29%
-13.86%
-14.16%
2.149
0.546
0.639
34.431
-21.20%
-520.06%
-11.81%

What the Analysts think about Fulgent Genetics

Analyst Ratings

Majority rating from 3 analysts.
Hold

Fulgent Genetics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-20.80% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$64M
-8.65%
Net income
-$13M
-89.54%
Profit margin
-20.80%
-88.55%

Fulgent Genetics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 96.88%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.08
-$0.39
$0.28
-$0.01
-
Expected
-$0.33
-$0.33
-$0.29
-$0.32
-$0.30
Surprise
-75.61%
18.18%
-197.67%
-96.88%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Fulgent Genetics stock?

Fulgent Genetics (FLGT) has a market cap of $618M as of June 22, 2024.

What is the P/E ratio for Fulgent Genetics stock?

The price to earnings (P/E) ratio for Fulgent Genetics (FLGT) stock is 0 as of June 22, 2024.

Does Fulgent Genetics stock pay dividends?

No, Fulgent Genetics (FLGT) stock does not pay dividends to its shareholders as of June 22, 2024.

When is the next Fulgent Genetics dividend payment date?

Fulgent Genetics (FLGT) stock does not pay dividends to its shareholders.

What is the beta indicator for Fulgent Genetics?

Fulgent Genetics (FLGT) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Fulgent Genetics stock

Buy or sell Fulgent Genetics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing